Induction of the Platelet Release Reaction by Phytohemagglutinin
Overview
Authors
Affiliations
We have previously shown that the erythroagglutinating phytohemagglutinin (E-PHA) from Phaseolus vulgaris binds to the surface of intact human platelets and that adenylate cyclase activity in the particulate fraction of E-PHA-treated platelets is lower than in comparable controls. We now find that E-PHA induces release of [(14)C]serotonin from platelets. Release follows binding of E-PHA, and a haptenic inhibitor of E-PHA binding prevents induction of release. E-PHA does not produce platelet lysis and has little effect on [(14)C]serotonin uptake. Platelets possess approximately 300,000 receptor sites of E-PHA per cell, and we estimate that about 15% of these sites must be occupied by E-PHA to initiate the release reaction. Prior incubation of platelets with prostaglandin E(1), theophylline, or dibutyryl cyclic AMP prevents E-PHA-induced release, although these agents have little effect on E-PHA binding to platelets. Thrombin and E-PHA produce different rates and extents of serotonin release. Thrombin (1 U/ml) causes release of 75-85% of platelet [(14)C]-serotonin, with half-maximal release occurring less than 0.5 min after thrombin addition. E-PHA, however, induces release of only 30-60% of platelet serotonin at a 10-fold slower rate. In addition, utilizing electron microscopy, we have observed striking differences in the morphological changes that occur in platelets exposed to E-PHA as compared with thrombin. Thus, the platelet release reaction may be triggered in part by binding of E-PHA to the cell surface, but this reaction only partially resembles that produced by thrombin.
McEver R, Baenziger N, MAJERUS P J Clin Invest. 1980; 66(6):1311-8.
PMID: 6449521 PMC: 371616. DOI: 10.1172/JCI109983.
The effects of thrombin on phytohemagglutinin receptor sites in human platelets.
FEAGLER J, TILLACK T, Chaplin D, MAJERUS P J Cell Biol. 1974; 60(3):541-53.
PMID: 4207395 PMC: 2109233. DOI: 10.1083/jcb.60.3.541.
Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
Tollefsen D, Pestka C J Clin Invest. 1985; 75(2):496-501.
PMID: 3838317 PMC: 423524. DOI: 10.1172/JCI111725.
Inhibition of human platelet aggregation by monovalent antifibrinogen antibody fragments.
Tollefsen D, MAJERUS P J Clin Invest. 1975; 55(6):1259-68.
PMID: 1169259 PMC: 301881. DOI: 10.1172/JCI108045.
The perturbation of thrombin binding to human platelets by anions.
Shuman M, MAJERUS P J Clin Invest. 1975; 56(4):945-50.
PMID: 1159095 PMC: 301950. DOI: 10.1172/JCI108174.